In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Fennec Pharmaceuticals Inc.

https://fennecpharma.com/

Latest From Fennec Pharmaceuticals Inc.

August User Fee Calendar Features Gene Therapy, Analgesics, And Of Course Oncology

Sixteen applications are in line for US FDA decisions in August. Ten are novel agents.

US FDA Performance Tracker Drug Review

Coronavirus Update: India Approves Remdesivir, Ex-Biogen Employee Charged

A former employee of Biogen is officially charged in China for allegedly jeopardizing public health, Wuhan tests 10 million residents, India approves remdesivir.

Coronavirus COVID-19 BioPharmaceutical

Finance Watch: Ayala Launches First Biopharma IPO In May

The cancer drug developer raised $55m. Also, Lyra raised $56m in the last of four biopharma IPOs in April, Biogen sold $3bn worth of debt, Oberland raised a $1.05bn fund and Praxis launched with more than $100m. 

Financing Innovation

Fennec Banks On EMA’s Seldom-Used PUMA For Sodium Thiosulfate

Fennec Pharmaceuticals says that its new formulation of sodium thiosulfate for preventing cisplatin-induced hearing loss in children targets a critical unmet medical need.

Drug Review Europe
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Adherex Technologies Inc.
    • Cadherin Biomedical, Inc.
    • Fennec Pharmaceuticals (EU) Limited
    • Oxiquant, Inc.
UsernamePublicRestriction

Register